Amicogen, Inc. (KOSDAQ:092040)
886.00
-60.00 (-6.34%)
Nov 20, 2026, 3:30 PM KST
Amicogen Revenue
Amicogen had revenue of 11.54B KRW in the quarter ending September 30, 2026, with 13.76% growth. This brings the company's total for the last twelve months to 48.08B, down -45.34% year-over-year. In the year 2025, Amicogen had annual revenue of 41.98B, down -75.82%. That makes Amicogen the 30,322nd largest company in the world by revenue and 1,895th in South Korea.
Revenue (ttm)
48.08B
Revenue Growth
-45.34%
P/S Ratio
1.30
Revenue / Employee
220.56M
Employees
218
Market Cap
62.42B
Revenue by Segment
Fiscal year ended Dec 31, 2024 See the full Amicogen breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.98B | -131.62B | -75.82% |
| Dec 31, 2024 | 173.60B | 13.70B | 8.57% |
| Dec 31, 2023 | 159.90B | 15.61B | 10.82% |
| Dec 31, 2022 | 144.30B | 19.41B | 15.55% |
| Dec 31, 2021 | 124.88B | 9.02B | 7.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HLB Therapeutics | 64.45B |
| ORIENT BIO | 59.09B |
| Prestige BioPharma | 26.07B |
| GeneOne Life Science | 12.37B |
| Anterogen.Co.,Ltd. | 9.29B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| IMB Dx | 5.60B |